Semaglutide vs Tirzepatide
How Semaglutide and Tirzepatide differ on mechanism, dosing, and the strength of the evidence behind each.
How this is graded
Every compound below carries a REGEN research grade, from S (regulatory approval behind the use it is bought for) down to F (no clinical evidence). Ordering follows that grade rather than search volume, so the compound at the top is the one with the most evidence, not the one most often sold. Doses are those reported in published protocols and are not recommendations.
Semaglutide
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist that slows gastric emptying, increases satiety, and improves insulin sensitivity and glucose control. Originally developed for type 2 diabetes, it has become a leading weight-loss therapy. Dosing is titrated up slowly over weeks to minimize gastrointestinal side effects like nausea. It directly affects metabolic markers — expect improvements in HbA1c, fasting glucose, and body composition. Not typically stacked with growth or healing peptides; used as a standalone metabolic tool.
Tirzepatide
Tirzepatide is a dual agonist that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, combining two incretin pathways for appetite suppression, improved insulin sensitivity, and weight loss. Trials show it produces greater average weight loss than semaglutide. Like other incretin mimetics it is titrated slowly to manage GI side effects. It strongly moves metabolic markers and is used as a standalone metabolic intervention. Monitor blood glucose, especially if combined with other glucose-lowering agents.
Evidence compared
| Semaglutide | Tirzepatide | |
|---|---|---|
| Research grade | Sgrade | Sgrade |
| Reported dose | 0.25–2.4 mg | 2.5–15 mg |
| Frequency | 1x weekly (titrated) | 1x weekly (titrated) |
| Half-life | ~7 days | ~5 days |
| Routes | subcutaneous, oral | subcutaneous |
| Tracked outcomes | Weight Loss, Immune Function, Body Composition, Muscle Growth, Cognitive Function | Weight Loss, Immune Function, Body Composition, Muscle Growth, Sleep Quality |
| Contraindications | personal/family history of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy | personal/family history of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy |
Which has more behind it
Semaglutide and Tirzepatide sit at the same research grade (S), so the choice between them turns on mechanism and tolerability rather than evidence weight. Both entries link through to the full reference, where the trial list and citations for each claim are set out in full.
Full Semaglutide reference · Full Tirzepatide reference
At a glance
| Compound | Grade | Reported dose | Half-life |
|---|---|---|---|
| Semaglutide | Sgrade | 0.25–2.4 mg · 1x weekly (titrated) | ~7 days |
| Tirzepatide | Sgrade | 2.5–15 mg · 1x weekly (titrated) | ~5 days |
Frequently asked questions
Semaglutide or Tirzepatide, which has better evidence?
Semaglutide and Tirzepatide sit at the same research grade (S), so the choice between them turns on mechanism and tolerability rather than evidence weight.
Can Semaglutide and Tirzepatide be used together?
The catalog does not list Semaglutide and Tirzepatide as a common pairing. Combining compounds does not combine their evidence.
What doses are reported for Semaglutide?
Published protocols report 0.25–2.4 mg, 1x weekly (titrated). This is what the literature describes, not a recommendation.
References
- Once-Weekly Semaglutide in Adults with Overweight or Obesity · Wilding JPH, et al. · 2021
- FDA Approval Announcement for Wegovy (2021). · 2021
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. · Lincoff AM, Brown-Frandsen K, Colhoun HM et al. · 2023
- Semaglutide, a glucagon like peptide-1 receptor agonist with ... - NIH · Mahapatra MK, Karuppasamy M, Sahoo BM · 2022
- Semaglutide Mechanism of Action Review. PMC. · Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A · 2022
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. · McGuire DK, Marx N, Mulvagh SL et al. · 2025
- Semaglutide | C187H291N45O59 | CID 56843331 - PubChem - NIH
- Central Nervous System Effects of GLP-1 Agonists. Nature Medicine.
- Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. · McGuire DK, Busui RP, Deanfield J et al. · 2023
- Semaglutide - StatPearls - NCBI Bookshelf
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021. · Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MT, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF · 2021
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. · Perkovic V, Tuttle KR, Rossing P et al. · 2024
- Molecular mechanisms of semaglutide and liraglutide as a ... · Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S, Guevara-Ramírez P, Paz-Cruz E, Zambrano-Villacres R, Simancas-Racines D, Zambrano AK · 2024
- Tirzepatide Once Weekly for the Treatment of Obesity · Jastreboff AM, et al. · 2022
- Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. · Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K · 2021
- Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. · Nicholls SJ, Bhatt DL, Buse JB et al. · 2024
- Tirzepatide - StatPearls - NCBI Bookshelf
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. · Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A · 2022
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. · Nicholls SJ, Pavo I, Bhatt DL et al. · 2025
- Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. · 2023
- Mounjaro FDA Label
- Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398(10295):143-155. · 2021
- Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. · Heerspink HJL, Sattar N, Pavo I et al. · 2022
- FDA Approves First Medication for Obstructive Sleep Apnea
- Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness. Cardiovasc Diabetol. 2022;21(1):66. · Liu HX, Ma JZ, Ye YS, Zhao JJ, Wan SJ, Hu XY, Xu G · 2022